Table 3.
Correlations between MET amplification and various clinicopathological parameters of gallbladder cancer patients
| Characteristic | No. | Method A |
Method B |
Method C |
Method D |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | p-value | Negative | Positive | p-value | Negative | Positive | p-value | Negative | Positive | p-value | ||
| Age (yr) | |||||||||||||
| < 65 | 47 | 40 (85.1) | 7 (14.9) | 0.432 | 42 (89.4) | 5 (10.6) | > 0.99 | 41 (87.2) | 6 (12.8) | > 0.99 | 42 (89.4) | 5 (10.6) | 0.759 |
| ≥ 65 | 46 | 36 (78.3) | 10 (21.7) | 42 (91.3) | 4 (8.7) | 40 (87.0) | 6 (13.0) | 40 (87.0) | 6 (13.0) | ||||
| Sex | |||||||||||||
| Male | 36 | 30 (83.3) | 6 (16.7) | 0.791 | 31 (86.1) | 5 (13.9) | 0.301 | 31 (86.1) | 5 (13.9) | > 0.99 | 31 (86.1) | 5 (13.9) | 0.745 |
| Female | 57 | 46 (80.7) | 11 (19.3) | 53 (93.0) | 4 (7.0) | 50 (87.7) | 7 (12.3) | 51 (89.5) | 6 (10.5) | ||||
| Histological grade | |||||||||||||
| G1, G2 | 69 | 60 (87.0) | 9 (13.0) | 0.038 | 66 (95.7) | 3 (4.3) | 0.011 | 64 (92.8) | 5 (7.2) | 0.011 | 65 (94.2) | 4 (5.8) | 0.006 |
| G3 | 19 | 12 (63.2) | 7 (36.8) | 14 (73.7) | 5 (26.3) | 13 (68.4) | 6 (31.6) | 13 (68.4) | 6 (31.6) | ||||
| T category | |||||||||||||
| Tis, T1, T2 | 61 | 56 (91.8) | 5 (8.2) | 0.001 | 59 (96.7) | 2 (3.3) | 0.007 | 58 (95.1) | 3 (4.9) | 0.003 | 58 (95.1) | 3 (4.9) | 0.007 |
| T3, T4 | 32 | 20 (62.5) | 12 (37.5) | 25 (78.1) | 7 (21.9) | 23 (71.9) | 9 (28.1) | 24 (75.0) | 8 (25.0) | ||||
| N category | |||||||||||||
| N0 | 46 | 41 (89.1) | 5 (10.9) | 0.011 | 45 (97.8) | 1 (2.2) | 0.003 | 44 (95.7) | 2 (4.3) | 0.003 | 44 (95.7) | 2 (4.3) | 0.006 |
| N1, N2 | 33 | 21 (63.6) | 12 (36.4) | 25 (75.8) | 8 (24.2) | 23 (69.7) | 10 (30.3) | 24 (72.7) | 9 (27.3) | ||||
| M category | |||||||||||||
| M0 | 86 | 69 (80.2) | 17 (19.8) | 0.342 | 77 (89.5) | 9 (10.5) | > 0.99 | 74 (86.0) | 12 (14.0) | 0.367 | 75 (87.2) | 11 (12.8) | 0.593 |
| M1 | 7 | 7 (100) | 0 | 7 (100) | 0 | 7 (100) | 0 | 7 (100) | 0 | ||||
| AJCC stage | |||||||||||||
| I, II | 48 | 46 (95.8) | 2 (4.2) | < 0.001 | 47 (97.9) | 1 (2.1) | 0.013 | 47 (97.9) | 1 (2.1) | 0.001 | 47 (97.9) | 1 (2.1) | 0.003 |
| III, IV | 45 | 30 (66.7) | 15 (33.3) | 37 (82.2) | 8 (17.8) | 34 (75.6) | 11 (24.4) | 35 (77.8) | 10 (22.2) | ||||
| Lymphovascular invasion | |||||||||||||
| Absent | 49 | 43 (87.8) | 6 (12.2) | 0.181 | 46 (93.9) | 3 (6.1) | 0.466 | 45 (91.8) | 4 (8.2) | 0.336 | 46 (93.9) | 3 (6.1) | 0.180 |
| Present | 43 | 33 (76.7) | 10 (23.3) | 38 (88.4) | 5 (11.6) | 36 (83.7) | 7 (16.3) | 36 (83.7) | 7 (16.3) | ||||
| Perineural invasion | |||||||||||||
| Absent | 58 | 50 (86.2) | 8 (13.8) | 0.161 | 55 (94.8) | 3 (5.2) | 0.067 | 54 (93.1) | 4 (6.9) | 0.026 | 55 (94.8) | 3 (5.2) | 0.015 |
| Present | 33 | 24 (72.7) | 9 (27.3) | 27 (81.8) | 6 (18.2) | 25 (75.8) | 8 (24.2) | 25 (75.8) | 8 (24.2) | ||||
Values are presented as number (%). AJCC, American Joint Committee on Cancer.